

# The RE-ENERGIZE study: a RandomisEd trial of ENtERAl Glutamine to minimIZE thermal injury

<b>Submission date</b> 13/01/2010	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 20/01/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 13/03/2019	<b>Condition category</b> Injury, Occupational Diseases, Poisoning	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Paul Wischmeyer

**Contact details**  
University of Colorado Denver  
Department of Anesthesiology  
12700 East 19th Avenue  
RC2, Room 7119  
Aurora  
United States of America  
80045  
+1 (0)720 848 6745  
paul.wischmeyer@ucdenver.edu

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
Nil known

**ClinicalTrials.gov (NCT)**  
NCT00985205

**Protocol serial number**  
CIHR #190808, MCT-94834; DOD# 09155001

# Study information

## Scientific Title

Effects of enteral glutamine supplementation on mortality and infectious morbidity in severely burned patients: a multicentre randomised double blind controlled trial

## Acronym

RE-ENERGIZE

## Study objectives

This research proposal is based on the following hypotheses:

1. Enteral glutamine administration decreases in-hospital mortality in adult subjects with severe thermal burn injuries
2. Enteral glutamine administration decreases infectious morbidity and shortens length of care in adult subjects with severe thermal burn injuries
3. Enteral glutamine administration decreases the cost of care of adult subjects with severe thermal burn injuries

As of 21/03/2012, the following changes have been made to the record.

Anticipated start date has been modified from 01/06/2010 to 01/12/2010.

Anticipated end date has been modified from 01/06/2012 to 01/03/2013.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Added on 21/03/2012:

Ethics approval expires on 7th February 2013.

Added 25/05/2010:

Colorado Multiple Institutional Review Board approved on the 7th April 2010 (ref: 10-0046).

Expires 6th April 2011.

## Study design

Multicentre randomised double-blind controlled trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Severe thermal burn injuries

## Interventions

Patients will be randomly allocated to two groups:

Glutamine group:

Patients will receive glutamine (L-glutamine) powder mixed with water through their feeding

tube, every 4 hours or three times a day if given orally, for a total of 0.5 g/kg/day. The glutamine powder will be supplied in pre-packaged aliquots of 5 grams and will be delivered to the ICU in blinded sachets and will be mixed in with water at the bedside by the patient's nurse.

Control group:

Patients will receive maltodextrin (placebo) mixed with water instead of glutamine.

Joint sponsor details:

Université de Montreal (Canada)  
C.P. 6128, succursale Centre-ville  
Montréal (Québec) H3C 3J7  
Canada  
<http://www.umontreal.ca>

University of Colorado (USA)  
Department of Anesthesiology  
12700 East 19th Avenue  
Aurora 80045  
United States of America  
<http://www.ucdenver.edu>

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome(s)**

Death: Hospital mortality recorded until complete healing, defined as 7 days after the last grafting procedure.

### **Key secondary outcome(s)**

1. Six-month mortality: mortality recorded during the 6 months following admission
2. Incidence of infections: according to the Centers for Disease Control and Prevention (CDC) or similar definitions for ventilation-related pneumonia, central line infection, positive blood culture, including germ identification, wound infection. Others: unusual infection such as abscesses, meningitis, peritonitis, etc.
3. Length of care (defined as length of healing): defined as 7 days after the last grafting operation
4. Length of mechanical ventilation: number of days on ventilator
5. Clinical status in the ICU: APACHE score at entry and SOFA score every day during the ICU stay until the discontinuation of mechanical ventilation. These scores are derived from the clinical and biological monitoring of the patients in the ICU and are standardised. All data needed for the calculation of these scores will be transferred to our electronic database and calculated automatically.
6. Length of time in the ICU. This will include all days with assisted ventilation. When a patient will be re-admitted to the ICU within 48 hrs for assisted ventilation after having been discharged, the total ventilation/day will be taken into account.

### **Completion date**

01/06/2012

# Eligibility

## Key inclusion criteria

Current inclusion criteria as of 21/03/2012

1. Total Burn Surface Area (TBSA):  
TBSA  $\geq$  20% for patients ages 18 - 59 years OR  
TBSA  $\geq$  10% for patients ages 60 - 80 years
2. Deep 2nd and/or 3rd degree burns requiring grafting
3. Age + TBSA = 40-119

Previous inclusion criteria

1. Age + total burn surface area (TBSA) = 60 - 120 (upper limit not included)
2. Deep 2nd and/or 3rd degree burns
3. TBSA greater than or equal to 20%

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Lower age limit

18 years

## Sex

All

## Key exclusion criteria

Current exclusion criteria as of 21/03/2012

1. > 72 hrs from admission to ICU to time of consent
2. Patients > 80 yrs or < 18 yrs of age
3. Liver cirrhosis - Child s class C liver disease
4. Pregnancy
5. Absolute contra-indication for EN (intestinal occlusion or perforation, abdominal injury)
6. Patients admitted > 48 hrs post burn (for patients that receive standardized burn care and resuscitation prior to admission to ICU, this exclusion criteria may be extended to Patients admitted > 96 hrs post burn; if this is the case consent must be obtained within 24 hrs of admission to burn ICU according to the judgement of the Site Investigator)
7. Patients with injuries from high voltage electrical shock
8. Patients who are moribund
9. Patients with BMI < 18 or > 50
10. Enrollment in another industry sponsored ICU intervention study (co-enrollment in academic studies will be considered on a case by case basis)

11. Received glutamine supplement for > 24 hrs prior to randomization
12. Known allergy to maltodextrin, corn starch, corn, or corn products

#### Previous exclusion criteria

1. Greater than 48 hours from admission to intensive care unit (ICU) to time of consent
2. Patients older than 80 years or younger than 18 years of age (age of maturity for an eligible patient to obtain consent is 18 years in Canada and in the United States of America)
3. Liver cirrhosis: Child's class C liver disease
4. Pregnancy (urine/blood tests for pregnancy will be done on all women of childbearing age by each site as part of standard of ICU practice)
5. Associated multiple fractures or severe head trauma
6. Absolute contra-indication for enteral nutrition (EN): intestinal occlusion or perforation, abdominal injury
7. Patients admitted more than 48 hours post-burn (for patients that receive standardised burn care and resuscitation prior to admission to ICU, this exclusion criteria may be extended to "Patients admitted more than more than 72 hours post-burn" according to the judgement of the Site Investigator)
8. Patients with injuries from high voltage electrical shock
9. Patients who are moribund
10. Patients with extreme body sizes: body mass index (BMI) less than 18 or greater than 50 kg /m<sup>2</sup>
11. Enrolment in another industry sponsored ICU intervention study (co-enrolment in academic studies will be considered on a case by case basis)

#### Date of first enrolment

01/06/2010

#### Date of final enrolment

01/06/2012

## Locations

#### Countries of recruitment

Canada

United States of America

#### Study participating centre

University of Colorado Denver

Aurora

United States of America

80045

## Sponsor information

#### Organisation

Clinical Evaluation Research Unit (CERU) (Canada)

**ROR**

<https://ror.org/02nkfan21>

## **Funder(s)**

**Funder type**

Research organisation

**Funder Name**

Canadian Institutes of Health Research - <http://www.cihr-irsc.gc.ca> (ref: 190808, MCT-94834)

**Alternative Name(s)**

Instituts de Recherche en Santé du Canada, Canadian Institutes of Health Research (CIHR), CIHR\_IRSC, Canadian Institutes of Health Research | Ottawa ON, CIHR - Welcome to the Canadian Institutes of Health Research, CIHR, IRSC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

Canada

**Funder Name**

U.S. Department of Defense (ref: 09155001)

**Alternative Name(s)**

United States Department of Defense, Department of Defense, U.S. Dept of Defense, US Department of Defense, US Dept of Defense, DOD, USDOD

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United States of America

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	protocol	12/12/2017	13/03/2019	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes